S
Scott M. Lippman
Researcher at University of California, San Diego
Publications - 676
Citations - 66362
Scott M. Lippman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 109, co-authored 651 publications receiving 60987 citations. Previous affiliations of Scott M. Lippman include Cleveland Clinic & Columbia University.
Papers
More filters
Journal ArticleDOI
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Vassiliki A. Papadimitrakopoulou,William N. William,Andrew J. Dannenberg,Scott M. Lippman,J. Jack Lee,Frank G. Ondrey,Douglas E. Peterson,Lei Feng,Anthea Atwell,Adel K. El-Naggar,Cherie-Ann Nathan,Joseph I. Helman,Baoheng Du,Bevan Yueh,Jay O. Boyle +14 more
TL;DR: Celecoxib at 100 or 200 mg twice daily was ineffective in controlling OPLs in this randomized controlled trial and cardiovascular toxicity results of other (large scale) randomized controlled trials of selective COX-2 inhibitors have discouraged the continued investigation of these agents in oral cancer chemoprevention.
Journal ArticleDOI
Genetic Variation in MicroRNA Genes and Risk of Oral Premalignant Lesions
Jessica Clague,Scott M. Lippman,Hushan Yang,Michelle A.T. Hildebrandt,Yuanqing Ye,J. Jack Lee,Xifeng Wu +6 more
TL;DR: First epidemiologic evidence is presented supporting that individual as well as combined genotypes of miRNA‐related variants may be used to predict the risk of OPL, and may be useful for identifying patients with OPL at high risk for progression to oral cancer.
Journal ArticleDOI
The Prognostic and Biological Significance of Cellular Heterogeneity in Medullary Thyroid Carcinoma: A Study of Calcitonin, L-Dopa Decarboxylase, and Histaminase
TL;DR: It is concluded that cellular heterogeneity in MTC tissue is associated with a distinct biochemical pattern, and its presence, whether in a primary or metastatic lesion, indicates a virulent neoplasmassociated with a grave prognosis.
Journal ArticleDOI
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco,Ruifeng Chen,Francis P. Worden,Deborah J.L. Wong,Douglas Adkins,Paul L. Swiecicki,Wanxing Chai-Ho,Peter Oppelt,Debanjali Ghosh,Julie Bykowski,Alfredo A. Molinolo,Emily Pittman,M. Valeria Estrada,Kathryn A. Gold,Gregory A. Daniels,Scott M. Lippman,Amanda Natsuhara,Karen Messer,Ezra E.W. Cohen +18 more
TL;DR: Pembrolizumab combined with cetuximab shows promising clinical activity for recurrent or metastatic HNSCC, and merits further investigation.
Journal ArticleDOI
Finasteride Improves the Sensitivity of Digital Rectal Examination for Prostate Cancer Detection
Ian M. Thompson,Catherine M. Tangen,Phyllis J. Goodman,M. Scott Lucia,Howard L. Parnes,Scott M. Lippman,Charles A. Coltman +6 more
TL;DR: The sensitivity of digital rectal examination was significantly greater for cancer detection in men receiving finasteride than placebo (21.3% vs 16.7%, p=0.015) and digital Rectal examination sensitivity was greater for detecting higher grade tumors.